Morning or evening? timing your RA pill could boost relief

NCT ID NCT07674134

Recruiting now Disease control Sponsor: Centre Hospitalier Princesse Grace Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study tests whether taking a once-daily JAK inhibitor for rheumatoid arthritis in the evening works better than taking it in the morning. About 90 adults with RA who qualify for this medication will be randomly assigned to morning or evening dosing. Researchers will compare how many people achieve a good response (based on EULAR criteria) and track side effects and disease activity over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JAK inhibitor (taken once daily)
What this could lead to: If timing matters, this could help people with rheumatoid arthritis get better symptom control by simply adjusting when they take their medication.
What could go wrong: This is a small study (90 people) looking at timing, not a new drug. The benefit may be small or not apply to everyone, and side effects could still occur regardless of timing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS (RA)

Contacts and locations

Locations

Centre Hospitalier Princesse Grace
RECRUITING

Monaco, 98000, Monaco

More trials for these conditions

Other studies related to the condition(s) this trial covers.